Macular Degeneration Clinical Trial
— BURGUNDYOfficial title:
A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)
Status | Recruiting |
Enrollment | 251 |
Est. completion date | December 29, 2027 |
Est. primary completion date | February 9, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Part 1, Part 2 and Part 3 Inclusion Criteria: - Willing to allow AH collection. Part 1 and Part 2 Ocular Inclusion Criteria for Study Eye: - Choroidal neovascularization (CNV) exclusively due to age-related macular degeneration (AMD). - Anti-vascular endothelial growth factor (VEGF) or anti-VEGF/Angiopoietin-2 (Ang-2) IVT treatment-naïve, or pre-treated with anti-VEGF or anti-VEGF/Ang-2 no less than two months prior to Day 1. - Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) images. - Decreased BCVA attributable primarily to nAMD, with BCVA letter score of 78 to 34 letters (inclusive) on ETDRS-like charts at screening. In case both eyes of a participant are eligible, the eye with the lower BCVA score should become the study eye. Part 3 Ocular Inclusion Criteria for Study Eye: - CNV exclusively due to AMD. - Diagnosis of nAMD within nine months prior to the screening visit. - Previous treatment with at least two IVT anti-VEGF or anti-VEGF/Ang-2 administrations IVT for nAMD. The last IVT administration must have occurred at least 21 days prior to the screening visit. - Demonstrated response to prior IVT anti-VEGF or anti-VEGF/Ang-2 treatment since diagnosis. - Availability of historical VA data prior to the first anti-VEGF or anti-VEGF/Ang-2 treatment for nAMD. - Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading. - Decreased BCVA attributable primarily to nAMD with letter score of 78 to 34 letters (inclusive) or better on ETDRS-like charts. Exclusion Criteria for Study Eye: - History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any planned surgical intervention during the study period. - Cataract surgery without complications within three months preceding the screening visit or planned during the study period. - Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also an exclusion criterion, unless it occurred as a result of yttrium-aluminum garnet laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation. - Prior macular treatment with verteporfin, external beam radiation therapy, transpupillary thermotherapy, or any type of laser photocoagulation. - Prior treatment with IVT corticosteroids or implant (e.g., triamcinolone, ozurdex, iluvien). - Subretinal hemorrhage >50% of the total lesion area and/or involving the fovea. - Subfoveal fibrosis or subfoveal atrophy. - Retinal pigment epithelial tear involving the macula. - History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant. - History of rhegmatogenous retinal tears or peripheral retinal breaks within three months prior to the screening visit. - Actual or history of myopia >-8 diopters. - Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure (IOP) >25 millimeters of mercury (mm Hg) or a cup to disc ration >0.8, despite treatment with antiglaucoma medication) and any such condition the Investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study. - Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal membrane with traction, macular hole) that, in the opinion of the Investigator, could either: - Require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; or - Likely contribute to loss of BCVA over the study period if allowed to progress untreated; or - Preclude any visual improvement due to substantial structural damage. - Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PD implant. - Prior treatment with any medication for geographic atrophy. - Prior treatment with any anti-VEGF-C or anti-VEGF-D inhibitors. Exclusion Criteria for Fellow Eye - BCVA letter score using ETDRS charts of < 34 letters. - Treatment with anti-VEGF or anti-VEGF/Ang-2 agents within one month prior to Day 1 (for Part 1) or prior to the randomization visit (Part 3). Exclusion Criteria for Either Eye - CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, uveitis or central serous chorioretinopathy. - Prior participation in a clinical trial involving anti-VEGF drugs within six months prior to the screening visit, other than ranibizumab, aflibercept, or faricimab. - Active intraocular inflammation (grade trace or above), infectious conjunctivitis, keratitis, scleritis, or endophthalmitis. - History of uveitis, including history of any intraocular inflammation following intravitreal anti-VEGFor anti-VEGF/Ang-2 injections. - Prior treatment with brolucizumab. - Prior gene therapy for nAMD |
Country | Name | City | State |
---|---|---|---|
United States | Southeast Retina Center | Augusta | Georgia |
United States | Austin Clinical Research LLC | Austin | Texas |
United States | Austin Research Center for Retina | Austin | Texas |
United States | Retina & Vitreous of Texas | Bellaire | Texas |
United States | Envision Ocular, LLC | Bloomfield | New Jersey |
United States | Midwest Vision Research Foundation | Chesterfield | Missouri |
United States | Southwest Retina Consultants | Durango | Colorado |
United States | Cumberland Valley Retina Associates | Hagerstown | Maryland |
United States | Southeastern Retina Associates | Knoxville | Tennessee |
United States | Piedmont Eye Center | Lynchburg | Virginia |
United States | Barnet Dulaney Perkins Eye Center | Mesa | Arizona |
United States | Tennessee Retina PC. | Nashville | Tennessee |
United States | Mid Atlantic Retina - Wills Eye Hospital | Philadelphia | Pennsylvania |
United States | Associated Retina Consultants | Phoenix | Arizona |
United States | Sierra Eye Associates | Reno | Nevada |
United States | Retina Vitreous Assoc of FL | Saint Petersburg | Florida |
United States | Spokane Eye Clinical Research | Spokane | Washington |
United States | Southern Vitreoretinal Assoc | Tallahassee | Florida |
United States | Retina Associates of Florida, LLC | Tampa | Florida |
United States | Retina Consultants of Texas | The Woodlands | Texas |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Ocular and Systemic (Nonocular) Adverse Events (AEs) | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Percentage of Participants with Ocular and Systemic (Nonocular) AEs during Post-operative and Follow-up Periods | Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48) | ||
Primary | Percentage of Participants with Adverse Events of Special Interest (AESIs) including Ocular AESIs | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Percentage of Participants with AESIs including Ocular AESIs during the Postoperative and Follow-up periods | Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48) | ||
Primary | Duration of AESIs including Ocular AESIs | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Duration of AESIs including Ocular AESIs during the Postoperative and Follow-up periods | Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48) | ||
Primary | Percentage of Participants with Adverse Device Effects (ADEs) | Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Duration of ADEs | Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Percentage of Participants with Anticipated Serious ADEs (ASADEs) | Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Duration of ASADEs | Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48 | ||
Primary | Change from Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score | ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. | Part 3: Baseline (baseline visit, before implant insertion) to Week 48 | |
Secondary | Maximum Observed Concentration (Cmax) of Zifibancimig in Blood and Aqueous Humor (AH) | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144 | ||
Secondary | Time of Maximum Concentration Observed (Tmax) of Zifibancimig in Blood and AH | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144 | ||
Secondary | Concentration at the End of a Dosing Interval before the Next Dose Administration (Ctrough) of Zifibancimig in Blood and AH | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144 | ||
Secondary | Area Under the Curve (AUC) of Zifibancimig in Blood and AH | Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144 | ||
Secondary | Percentage of Participants who did not meet Supplemental Treatment Criteria for the PD implant with Zifibancimig | Part 3: Week 36, Week 40, and Week 44 | ||
Secondary | Percentage of Participants who Gained or Lost =15, =10 =5 or =0 letters in ETDRS-BCVA score from Baseline | ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. | Part 3: Baseline to Week 48 | |
Secondary | Change from Baseline in Central Subfield Thickness (CST) | Part 3: Baseline to Week 48 | ||
Secondary | Change from Baseline Over Time in CST | Part 3: Baseline to end of follow up period (up to Week 144) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |